Pre-Open Stock Movers 8/15: (KGJI) (ETRM) (PPS) Higher; (CYBR) (VUZI) (ABIL) Lower
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Kingold Jewelry (Nasdaq: KGJI) 32.2% HIGHER; reported Q2 EPS of $0.30, versus $0.01 reported last year. Revenue for the quarter came in at $390.3 million, versus $249.4 million reported last year.
EnteroMedics Inc. (Nasdaq: ETRM) 12.4% HIGHER; announced the publication of 24 month results from the Company's ReCharge Clinical Study. The article, titled "Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial," was published in Obesity Surgery (DOI: 10.1007/s11695-016-2325-7), and is available online here.
Post Properties, Inc. (NYSE: PPS) 11.5% HIGHER; MAA and Post Propertiesannounced that they have entered into a definitive merger agreement under which Post Properties, Inc. will merge with and into MAA, creating a Sunbelt-focused, publicly traded, multifamily REIT with enhanced capabilities to deliver superior value for residents, shareholders and employees. The combined company is expected to have a pro forma equity market capitalization of approximately $12 billion and a total market capitalization of approximately $17 billion.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) 7.0% HIGHER; reported topline results from the single-arm, open-label Phase 3 SAP302 trial (NCT02447848), which assessed ARX-04 (sufentanil sublingual tablet, 30 mcg) in patients who presented to the emergency room with moderate-to-severe acute pain associated with trauma or injury. Overall, the 76 adults treated with ARX-04 in this study experienced a mean pain intensity difference to baseline (PID) of 2.9 from a baseline of 8.1, or 35%, on a 0 – 10 numeric rating scale at 60 minutes.
MGT Capital Investments (NYSE: MGT) 5.4% HIGHER; Ascendiant Capital initiated coverage on MGT Capital Investments with a Buy rating and a price target of $6.
Sysco Corp. (NYSE: SYY) 4.5% HIGHER; reported Q4 EPS of $0.64, $0.03 better than the analyst estimate of $0.61. Revenue for the quarter came in at $13.6 billion versus the consensus estimate of $13.68 billion.
American Eagle Outfitters (NYSE: AEO) 3.0% HIGHER; Deutsche Bank upgraded American Eagle Outfitters from Hold to Buy with a price target of $22.00 (from $17.00).
CyberArk Software (Nasdaq: CYBR) 2.8% LOWER; Goldman Sachs downgraded CyberArk Software from Buy to Neutral with a price target of $58
Valeant Pharma (NYSE: VRX) 2.5% HIGHER; Mizuho upgrades Valeant Pharma from Underperform to Neutral and moves its price target from $11 up to $25.
Vuzix Corp. (Nasdaq: VUZI) 2.5% LOWER; reported Q2 EPS of ($0.28), $0.09 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $560.9 thousand versus the consensus estimate of $530 thousand.
Sidoti downgraded Haemonetics (NYSE: HAE) 2.0% LOWER; Sidoti downgraded Haemonetics from Buy to Neutral with a price target of $39 (unchanged).
Ability (Nasdaq: ABIL) 1.6% LOWER; reported Q2 EPS of ($0.13), versus $0.25 reported last year. Revenue for the quarter came in at $1 million, versus $21.2 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Liberty Mutual to Acquire Ironshore from Fosun for ~$3 Billion
- Pre-Open Stock Movers 12/01: (BSTG) (BLUE) (CLC) Higher; (ARDM) (HTBX) (PTN) Lower (more...)
- Cemex S.A. (CX) Offers to Acquire Trinidad Cement at 33% Premium
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesDeutsche Bank, Goldman Sachs, Sidoti & Company, Definitive Agreement, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!